Literature DB >> 7055803

Chlorpromazine distribution in hamsters and mice bearing transplantable melanoma.

R G Fairchild, D Greenberg, K P Watts, S Packer, H L Atkins, P Som, S J Hannon, A B Brill, I Fand, W P McNally.   

Abstract

Chlorpromazine (CPZ) distribution was measured in tissues of Syrian golden hamsters bearing Greene melanoma and in BALB/c mice bearing Harding-Passey melanoma. Distribution was evaluated as a function of time (0.5 to 14 days) and as a function of single and multiple doses (up to five) of from 5 to 50 mg CPZ per kg body weight. Routes of administration (i.p., i.v., p.o.) were compared. The physiological behavior of CPZ is of interest as it is used extensively as a tranquilizing drug (Thorazine). Further, since CPZ binds to the pigment melanin, the possibility exists of using CPZ to transport diagnostic or therapeutic agents to melanoma. It was found that, at 2 days postinjection, tumor/tissue concentration ratios exceeded 10 for metabolizing organs, such as liver and 100 for "back-ground" tissues, such as blood and muscle. Absolute concentrations of CPZ in tumor exceeding 100 microgram CPZ per g tumor were obtained with both single and multiple doses. This selective high concentration in tumor would make CPZ an ideal vehicle for the transport of boron to tumor for use in neutron capture therapy via the 10B(n, alpha)7Li reaction.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7055803

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Effect of thioridazine on experimental cutaneous staphylococcal infections.

Authors:  Beth L Hahn; Peter G Sohnle
Journal:  In Vivo       Date:  2014 Jan-Feb       Impact factor: 2.155

2.  Localization of 11C-radiopharmaceuticals in the Greene melanoma of hamsters.

Authors:  J H Turner; M Maziere; D Comar
Journal:  Eur J Nucl Med       Date:  1985

3.  Incorporation of chlorpromazine into bilayer liposomes for protection against microsomal metabolism and liver absorption.

Authors:  R A Schwendener
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Apr-Jun       Impact factor: 2.441

4.  In vivo toxicity of phenothiazines to cells of a transplantable tumor.

Authors:  S Lehnert
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Do phenothiazines contribute to tumour regressions in lymphokine-activated killer cell/interleukin-2 treatments of renal cell cancer?

Authors:  C Sauter
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.